Open AccessTotal Cholesterol Levels in Men with Schizophrenia Receiving Risperidone and Haloperidol Treatment
Author(s) -
Agusmita Agusmita,
Bahagia Loebis,
Muhammad Surya Husada,
Elmeida Effendy
Publication year - 2021
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2021.6333
Subject(s) - risperidone , haloperidol , medicine , schizophrenia (object oriented programming) , significant difference , cholesterol , dopamine antagonist , psychiatry , dopamine
AIM: The objectives of the study were to compare total cholesterol levels in men with schizophrenia receiving risperidone and haloperidol treatment.METHODS: We conducted on treatment analysis experiment study involving 30 subjects who received risperidone and 30 subjects who received haloperidol. Total cholesterol levels were examined at week 0 and week 8.RESULTS: There were no statistically significant differences in baseline characteristics. At week 8, mean of total cholesterol level in the risperidone group was 207.23 ± 21.49 compared to 188.17 ± 17.00 in the haloperidol group. A difference of 19.06 ± 5.00 (95% CI 9.05–29.08) was observed, which is statistically significant (p < 0.001).CONCLUSIONS: There was a statistically significant increase in total cholesterol levels in men with schizophrenia receiving risperidone compared to haloperidol.